Coenzyme Q10 for heart failure.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 35608922 · doi:10.1002/14651858.CD008684.pub3
What was done
This Cochrane systematic review searched multiple databases through late 2020 for randomized controlled trials (parallel or cross-over design) evaluating coenzyme Q10 compared to placebo or conventional therapy in patients with heart failure. Primary and secondary outcomes were pooled using risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals, and evidence certainty was graded using GRADE methodology.
What was found
The review included 11 randomized trials comprising 1,573 participants. Coenzyme Q10 probably reduces all-cause mortality (RR 0.58, 95% CI 0.35 to 0.95; 1 study, 420 participants; NNTB 13.3; moderate-quality evidence) and heart failure-related hospitalization (RR 0.62, 95% CI 0.49 to 0.78; 2 studies, 1,061 participants; NNTB 9.7; moderate-quality evidence). Very low-quality evidence suggested a small increase in left ventricular ejection fraction (MD 1.77, 95% CI 0.09 to 3.44; 7 studies, 650 participants). Findings were inconclusive for myocardial infarction (RR 1.62, 95% CI 0.27 to 9.59; 1 study, 420 participants), stroke (RR 0.18, 95% CI 0.02 to 1.48; 1 study, 420 participants), exercise capacity (MD 48.23, 95% CI -24.75 to 121.20; 3 studies, 91 participants), and adverse events (RR 0.70, 95% CI 0.45 to 1.10; 2 studies, 568 participants).
Why it matters
Coenzyme Q10 supplementation shows probable benefits for reducing heart failure hospitalizations and mortality, but overall evidence remains limited by methodological risks and inconsistent findings across secondary outcomes.
Limits
All included studies had unclear or high risk of bias in at least one domain. Major clinical outcomes including all-cause mortality, stroke, and myocardial infarction were each evaluated in only a single study of 420 participants. There was substantial variation in CoQ10 dosage and follow-up duration, and no trial evaluated validated quality-of-life scales, exercise hemodynamics, or cost-effectiveness.